Theraclone Sciences, Inc., a Seattle, Washington-based therapeutic antibody discovery and development company, raised an additional $10.6m extension to its Series B financing.
Backers include current investors ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures and Zenyaku Kogyo.
This funding, which brings the total round to $41m, will help Theraclone advance its clinical programs and support ongoing discovery projects using Theraclone’s I-STAR™ technology platform, which is designed for the rapid screening and identification of rare, potent and therapeutically-relevant human antibodies.
Led by Executive Chairman and acting CEO Steven Gillis, Ph.D., the company focuses on the development of novel therapeutic antibodies for the treatment of infectious disease and cancer.
FinSMEs
09/09/2011